Skip to content

Tempest Therapeutics, Inc.

Public company
Headquarters
BRISBANE, California
Ticker
TPST
CIK
0001544227

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

8
5 appointments, 3 departures

Last event

Oct 30, 2026
Executive departureCFO departs: Constance Ames

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
CFOConstance AmesOct 30, 2026Departed
CFOStephanie Horn-WarnockOct 30, 2026Appointed
Class III directorJohn FrederickOct 19, 2026Appointed
CFOConstance AmesSep 28, 2026Appointed
CFOJustin TrojanowskiAug 24, 2026Departed

Related companies

Same industry and state, with recent events.

  1. Executive departure

    CFO departs: Constance Ames

    Constance Ames, Chief Financial Officer of Tempest Therapeutics, Inc., resigns the role, effective October 26, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer

    Source: SEC 8-K, filed Oct 30, 2026

  2. Executive appointment

    CFO appointed: Stephanie Horn-Warnock

    Stephanie Horn-Warnock was named Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of Tempest Therapeutics, Inc., effective October 26, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary

    Source: SEC 8-K, filed Oct 30, 2026

  3. Executive appointment

    Class III director appointed: John Frederick

    John Frederick was named Class III director of Tempest Therapeutics, Inc., effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class III director

    Source: SEC 8-K, filed Oct 19, 2026

  4. Executive appointment

    Class III director appointed: Nancy Freda-Smith

    Nancy Freda-Smith was named Class III director of Tempest Therapeutics, Inc., effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class III director

    Source: SEC 8-K, filed Sep 28, 2026

  5. Executive departure

    CFO departs: Nicholas Rossettos

    Nicholas Rossettos, Chief Financial Officer of Tempest Therapeutics, Inc., resigns the role, effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer

    Source: SEC 8-K, filed Sep 28, 2026

  6. Executive appointment

    CFO appointed: Constance Ames

    Constance Ames was named Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of Tempest Therapeutics, Inc., effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary

    Source: SEC 8-K, filed Sep 28, 2026

  7. Executive departure

    CFO departs: Justin Trojanowski

    Justin Trojanowski, Principal Financial Officer of Tempest Therapeutics, Inc., resigns the role, effective September 1, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Principal Financial Officer

    Source: SEC 8-K, filed Aug 24, 2026

  8. Executive appointment

    CFO appointed: Nicholas Rossettos

    Nicholas Rossettos was named Chief Financial Officer of Tempest Therapeutics, Inc., effective September 1, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer

    Source: SEC 8-K, filed Aug 24, 2026

Last verified Nov 8, 2026